Gilead Sciences Revenue 2006-2021 | GILD

Gilead Sciences annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Gilead Sciences revenue for the quarter ending September 30, 2021 was $7.421B, a 12.83% increase year-over-year.
  • Gilead Sciences revenue for the twelve months ending September 30, 2021 was $27.482B, a 18.73% increase year-over-year.
  • Gilead Sciences annual revenue for 2020 was $24.689B, a 9.98% increase from 2019.
  • Gilead Sciences annual revenue for 2019 was $22.449B, a 1.46% increase from 2018.
  • Gilead Sciences annual revenue for 2018 was $22.127B, a 15.24% decline from 2017.
Gilead Sciences Annual Revenue
(Millions of US $)
2020 $24,689
2019 $22,449
2018 $22,127
2017 $26,107
2016 $30,390
2015 $32,639
2014 $24,890
2013 $11,202
2012 $9,702
2011 $8,385
2010 $7,949
2009 $7,011
2008 $5,336
2007 $4,230
2006 $3,026
2005 $2,028
Gilead Sciences Quarterly Revenue
(Millions of US $)
2021-09-30 $7,421
2021-06-30 $6,217
2021-03-31 $6,423
2020-12-31 $7,421
2020-09-30 $6,577
2020-06-30 $5,143
2020-03-31 $5,548
2019-12-31 $5,879
2019-09-30 $5,604
2019-06-30 $5,685
2019-03-31 $5,281
2018-12-31 $5,795
2018-09-30 $5,596
2018-06-30 $5,648
2018-03-31 $5,088
2017-12-31 $5,949
2017-09-30 $6,512
2017-06-30 $7,141
2017-03-31 $6,505
2016-12-31 $7,320
2016-09-30 $7,500
2016-06-30 $7,776
2016-03-31 $7,794
2015-12-31 $8,506
2015-09-30 $8,295
2015-06-30 $8,244
2015-03-31 $7,594
2014-12-31 $7,314
2014-09-30 $6,042
2014-06-30 $6,535
2014-03-31 $4,999
2013-12-31 $3,120
2013-09-30 $2,783
2013-06-30 $2,767
2013-03-31 $2,532
2012-12-31 $2,588
2012-09-30 $2,427
2012-06-30 $2,405
2012-03-31 $2,282
2011-12-31 $2,200
2011-09-30 $2,122
2011-06-30 $2,137
2011-03-31 $1,926
2010-12-31 $1,999
2010-09-30 $1,938
2010-06-30 $1,927
2010-03-31 $2,086
2009-12-31 $2,032
2009-09-30 $1,801
2009-06-30 $1,647
2009-03-31 $1,530
2008-12-31 $1,428
2008-09-30 $1,371
2008-06-30 $1,278
2008-03-31 $1,258
2007-12-31 $1,095
2007-09-30 $1,059
2007-06-30 $1,048
2007-03-31 $1,028
2006-12-31 $899
2006-09-30 $749
2006-06-30 $685
2006-03-31 $693
2005-12-31 $609
2005-09-30 $493
2005-06-30 $495
2005-03-31 $430
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $85.060B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00